Could a third chemo drug tame advanced endometrial cancer?
NCT ID NCT06102252
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding a drug called epirubicin to the standard two-drug chemotherapy (paclitaxel and carboplatin) helps people with advanced endometrial cancer. Sixty patients were enrolled to see if the three-drug combo is better at controlling the disease before surgery. The main goal was to see how many patients could complete all six cycles of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Paclitaxel, carboplatin, and epirubicin (chemotherapy drugs)
- What this could lead to
- If adding epirubicin works better, it could improve how well chemotherapy shrinks advanced endometrial cancer before surgery.
- What could go wrong
- This is a small, completed study with only 60 participants. Adding epirubicin may increase side effects without clear benefit, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag university Hospital
Sohag, Sohag, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a natural compound boost chemotherapy against endometrial cancer?
- Can a new nucleotide analogue boost cancer treatment?
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Scientists probe hidden clues to immunotherapy success in endometrial cancer